Trials no longer actively enrolling patients:
- AbbVie (M23-362) (AbbVie)– A Phase 2, Open-Label Trial to Evaluate Safety of Epcoritamab Monotherapy in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Classic Follicular Lymphoma (Previously Grade 1-3a) when Administered in the Outpatient Setting (NCT Number: NCT05451810)
- Amplitude (67652000PCR3002) (Janssen) – A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC) (NCT Number: NCT04497844)
- AVANZAR (D926NC00001) (AstraZeneca) – A Phase III, Randomized, Open-label, Multicentre, Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Durvalumab and Carboplatin Versus Pembrolizumab in Combination With Platinum-based Chemotherapy for the First-line Treatment of Patients With Locally Advanced or Metastatic NSCLC Without Actionable Genomic Alterations (NCT Number: NCT05687266)
- BDX-00146 (Biodesix Inc) – An Observational Study Assessing the Clinical Effectiveness of the VeriStrat® Test and Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer (INSIGHT) (NCT Number: NCT03289780)
- Bespoke IO 20-043-NCP (Natera) – A BESPOKE Study of ctDNA Guided Immunotherapy for Non-Small cell lung cancer, Melanoma, and Colorectal cancer. (NCT Number: NCT04761783)
- Bespoke 20-041-NCP (Natera) – An Observational Study of ctDNA Guided Therapy in Colorectal Cancer. (NCT Number: NCT04264702)
- CORFU (AstraZeneca) – Retrospective/Observational Study of Risk of Adverse Events in NSCLC Patients Treated with Immune Checkpoint Inhibitors Followed by EGFR Tyrosine Kinase Inhibitors
- BillionToOne (NS-001) (BillionToOne Inc) – Compare the clinical relevant biomarkers identified by a novel BillionToOne quantitative ctDNA somatic mutation profiling assay with clinically available comparable assays in patients with advanced stage solid tumors (IRB number: 20230250)
- EQ132-201 (EQRx) – A Phase 2 Study to Evaluate the Safety and Efficacy of Lerociclib in Participants with Advanced Breast Cancer (Sponsor: EQRx, Inc; NCT Number: NCT05085002)
- Furmo (Furmo-004) (ArriVent BioPharma, Inc) – A Global, Phase 3, Randomized, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Furmonertinib Compared to Platinum-Based Chemotherapy as First-Line Treatment for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT) (NCT Number: 05607550)
- G000 (BB-1701-G000-205) (Esai) – An Open-label, Multicenter, Phase 2 Dose Optimization and Expansion Study to Evaluate the Safety and Efficacy of BB-1701, an anti-human epidermal growth factor receptor 2 (anti-HER2) antibody-drug conjugate (ADC), in Previously Treated Subjects with HER2-positive or HER2-low Unresectable or Metastatic Breast Cancer (NCT Number: NCT06188559)
- I3Y-MC-JPCW(b) (Eli Lilly) – A Randomized, Double Blind, Placebo-Controlled Phase 3 Study of Abemaciclib plus Standard Adjuvant Endocrine Therapy in Participants with High-Risk, Node-Positive, HR+, HER2+ Early Breast Cancer Who Have Completed Adjuvant HER2-Targeted Therapy (NCT number: NCT04752332)
- KRYSTAL 12 (Mirati) – Phase 3 Study of MRTX849 vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-12) (NCT Number: NCT04685135)
- LOXO-BTK-20019 (Loxo Oncology, Inc) – Phase 3 Open-Label, Randomized Study of LOXO-305 versus Investigator Choice of BTK Inhibitor in Patients with Previously Treated BTK Inhibitor Naïve Mantle Cell Lymphoma (BRUIN MCL-321) (NCT Number: NCT04662255)
- PARADIGM (VastBiome) – Pursuit to Analyze and Reveal Associated Drivers of Immunotherapy outcomes through the Gut Microbiome (NCT Number: NCT05037825)
- Prevalence (Janssen Research & Development) – Biomarker Study to Determine Frequency of DNA-repair Defects in Men with Metastatic Prostate Cancer. Observational study (NCT number: NCT03871816)
- VIKTORIA-1 (Celcuity) – A Phase 3, Open-Label, Randomized, Two-Part Study Comparing Gedatolisib in Combination with Palbociclib and Fulvestrant to Standard-of-Care Therapies in Patients with HR-Positive, HER2-Negative Advanced Breast Cancer Previously Treated with a CDK4/6 Inhibitor in Combination with Non-Steroidal Aromatase Inhibitor Therapy (NCT Number: NCT05501886)